Dupixent bests placebo in clinical, histological outcomes in patients with EoE
CHARLOTTE, N.C. — Dupilumab improved clinical, symptomatic, histologic and endoscopic outcomes among patients treated for eosinophilic esophagitis, according to study results presented at the ACG Annual Scientific Meeting.“EoE is a chronic, progressive, type 2 inflammatory disease of the esophagus, leading to symptoms of esophageal dysfunction that can substantially affect quality of life. Some current treatment…